Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for India.
Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.
Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Resolve the exact identity of Tesamorelin through Check the FDA Purple Book product record from U.S. Food and Drug Administration. Then search Approved new drugs from Central Drugs Standard Control Organization for the destination product record and Drug and quality alerts from Central Drugs Standard Control Organization for the seller, establishment, or supply route in India. A match in one record does not replace the other two checks.
No. A page using the name Tesamorelin, local currency, a domestic delivery claim, or a familiar package image is only a lead. This record resolves seller-labelled 10 mg tesamorelin research listings. EGRIFTA WR is a separate FDA-licensed prescription product with a specific application, 11.6 mg presentation, indication, label, and regulated supply chain. The research listings do not inherit that approval. For India, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.
Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for India. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity source: Check the FDA Purple Book product record / U.S. Food and Drug Administration ↗A credible result must keep these separate. The official links answer different questions and should be checked in sequence.
Check the FDA Purple Book product record is maintained by U.S. Food and Drug Administration. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Check the FDA Purple Book product record ↗Approved new drugs is maintained by Central Drugs Standard Control Organization. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Approved new drugs ↗Drug and quality alerts is maintained by Central Drugs Standard Control Organization. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Drug and quality alerts ↗India's medicine oversight combines central responsibilities with state licensing and enforcement. CDSCO publishes new-drug approvals and quality or spurious-product alerts, but neither list by itself verifies a clinic, pharmacy, imported research listing, or local seller claim.
The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.
Search CDSCO's approved new-drug records for the exact name and approval period. Do not treat a foreign authorization, sponsor announcement, or ingredient match as an Indian approval entry.
Check CDSCO alerts for not-of-standard-quality and spurious batches. An approval record and a later batch alert answer different questions and both may matter.
Pharmacy and sale permissions may depend on the relevant State Drug Control authority, so match the business and jurisdiction instead of assuming a central product entry verifies the seller.
Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.